Drugs / Neoantigen Peptides
Neoantigen Peptides
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05475106 | May 2022 → Nov 2025 | neoplasm | Instituto de Medicina Regenerativa | Unknown | No outcome recorded |
| Phase 0 | NCT04509167 | Aug 2020 → Jun 2022 | neoplasm | Instituto de Medicina Regenerativa | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT05307835 | Dec 2021 → Jun 2026 overdue | esophageal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03068832 | Sep 2021 → Mar 2023 | brain cancer | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04810910 | Mar 2021 → Mar 2025 | pancreatic exocrine neoplasm | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT07504484 | Oct 2020 → Dec 2023 | colorectal cancer, non-small cell lung carcinoma | Ying Yuan, MD | Completed | No outcome recorded |
| Phase 1 | NCT04864379 | Sep 2020 → Aug 2025 | cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04072900 | Apr 2020 → Sep 2021 | cutaneous melanoma | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1 | NCT02950766 | Mar 2019 → Dec 2027 expected | kidney cancer | Patrick Ott, MD, PhD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03223103 | Mar 2018 → May 2029 expected | glioblastoma | Adilia Hormigo | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03662815 | Feb 2018 → May 2021 | cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03645148 | Oct 2017 → Nov 2020 | exocrine pancreatic carcinoma | Zhejiang Provincial People's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02510950 | Dec 2015 → Feb 2017 | glioblastoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT01970358 | Apr 2014 → Sep 2015 | melanoma | Patrick Ott, MD, PhD | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoAntigen peptides | “NeoAntigen peptides:4 x 2 mg the total peptides given on days 84，87，91，98，105，133，and 161” NCT04072900 ↗3“Neovax is a combination of Poly-ICLC and Neoantigen Peptides” NCT02950766 ↗ |
| Known as | iNeo-Vac-P01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07504484 ↗ |
| Known as | Peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01970358 ↗ |
| Known as | Personalized peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068832 ↗ |
| Action | Activate | “iNeo-Vac-P01 employs neoantigen peptides to activate the body's immune system” NCT07504484 ↗ |
| Modality | Vaccine | “Personalized Neoantigen Cancer Vaccine” NCT02950766 ↗ |
| Route | Subcutaneous | “vaccinated subcutaneously with adjuvant” PMID 32439700 ↗ May 2020 |